These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23860531)

  • 41. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
    Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era.
    Lim RMH; Chan NPX; Khoo LP; Cheng CL; Tan L; Poon EYL; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
    Sci Rep; 2020 Mar; 10(1):4373. PubMed ID: 32152442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The risk of melanoma in patients with chronic lymphocytic leukemia; a population-based study.
    Turk T; Saad AM; Al-Husseini MJ; Gad MM
    Curr Probl Cancer; 2020 Apr; 44(2):100511. PubMed ID: 32115255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.
    Kane E; Painter D; Smith A; Crouch S; Oliver S; Patmore R; Roman E
    Cancer Epidemiol; 2019 Apr; 59():236-243. PubMed ID: 30844679
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time.
    Lindström V; Hakkarainen KM; Mehtälä J; Klement R; Leval A; Järvinen TM
    Eur J Haematol; 2019 Sep; 103(3):190-199. PubMed ID: 31210368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.
    Parikh SA; Habermann TM; Chaffee KG; Call TG; Ding W; Leis JF; Macon WR; Schwager SM; Ristow KM; Porrata LF; Kay NE; Slager SL; Shanafelt TD
    Am J Hematol; 2015 Apr; 90(4):334-8. PubMed ID: 25581025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
    Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
    Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
    Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical characteristics and treatment response in adult patients with non-Hodgkin's chronic lymphocytic leukemia (CLL)].
    Sicras-Mainar A; Castro A; Navarro-Artieda R
    Gac Med Mex; 2016; 152(1):59-69. PubMed ID: 26927645
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience.
    Chavez JC; Dalia S; Sandoval-Sus J; Kharfan-Dabaja MA; Al-Ali N; Komrokji R; Padron E; Corrales-Yepez G; Rock-Klotz J; Pinilla-Ibarz J
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S14-8. PubMed ID: 26297266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan.
    Andrade-Campos MM; Liévano P; Espinosa-Lara N; Soro-Alcubierre G; Grasa-Ulrich JM; López-Gómez L; Baringo T; Giraldo P
    Eur J Haematol; 2016 Dec; 97(6):576-582. PubMed ID: 27157440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Familial chronic lymphocytic leukemia in Israel: A disproportionate distribution among Ashkenazi Jews.
    Zada M; Lerner D; Piltz Y; Perry C; Avivi I; Herishanu Y
    Eur J Haematol; 2017 Jul; 99(1):51-55. PubMed ID: 28370385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort.
    Seftel MD; Demers AA; Banerji V; Gibson SB; Morales C; Musto G; Pitz MW; Johnston JB
    Leuk Res; 2009 Nov; 33(11):1463-8. PubMed ID: 19581000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndrome.
    Hensel M; Buss EC; Tiemann M; Parwaresch R; Libicher M; Fruehauf S; Ho AD
    Eur J Haematol; 2004 Mar; 72(3):217-21. PubMed ID: 14962241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Composite lymphoma of the orbit treated with rituximab.
    Kang SJ; Schmack I; Wojno TH; Grossniklaus HE
    Ophthalmic Plast Reconstr Surg; 2007; 23(2):143-4. PubMed ID: 17413631
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.
    Brewer JD; Shanafelt TD; Call TG; Cerhan JR; Roenigk RK; Weaver AL; Otley CC
    Int J Dermatol; 2015 Aug; 54(8):e287-93. PubMed ID: 25772131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Head and neck squamous cell cancer associated with lymphoproliferative malignancies is aggressive.
    Li L; Hamilton L; Montgomery J; Stewart M
    J Laryngol Otol; 2020 May; 134(5):460-462. PubMed ID: 32308160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The implications of an incidental chronic lymphocytic leukaemia in a resection specimen for colorectal adenocarcinoma.
    Dennis RJ; Alberts JC
    World J Surg Oncol; 2007 Oct; 5():126. PubMed ID: 17971235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.